Neuronetics, Inc. (NASDAQ: STIM) has announced the issuance of inducement awards in the form of Restricted Stock Units (RSUs) ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on October 22, 2024, the ...

Each of the RSU grants vests ratably in equal installments on the first, second, and third anniversaries of the grant date, subject to the recipient’s continued service with the Company through the ...

PURCHASE, NY, Nov. 07, 2024 (GLOBE NEWSWIRE) -- (NYSE:TDOC), the global leader in whole-person virtual care, today announced ...

The stock options were granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the ...

SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on November 10, 2024, the Compensation Committee of its Board of Directors granted ...

Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients ...

AboutAltimmune Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a ...

(Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that on November 7, 2024, the ...

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting ...

The awards were made under the Company’s 2024 Inducement Stock Incentive Plan, with a grant date and vesting commencement date of November 1, 2024, and were approved by the compensation ...

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the Compensation Committee of its Board of Directors ...